Skip to main content
Premium Trial:

Request an Annual Quote

Biotheranostics, Syapse Ink Agreement to Offer Integrated Diagnostics Solution for Cancer

NEW YORK (GenomeWeb) – Biotheranostics and Syapse said this week that they plan to combine their respective products to offer a more integrated precision medicine solution for oncology.

Under the terms of the agreement, the partners will make Biotheranostics' CancerType ID and Breast Cancer Index genomic tests available through Syapse's precision medicine software platform, which is used by health systems and cancer care networks. The platform offers tools for integrating clinical, genomic, and other molecular data from medical records, labs, and pharmacies, as well as guidance to physicians on appropriate diagnostic and therapeutic strategies based on clinical best practices.

For its part, Biotheranostics' tests provide molecular profiles for patients with early stage breast cancer and metastatic cancer. Its breast cancer index helps oncologists make decisions about extended endocrine therapy for estrogen-receptor-positive early stage breast cancer patients. The test helps physicians predict the risk of late disease recurrence and identify which patients are likely to benefit from continuing adjuvant endocrine therapy beyond five years. Meanwhile, its CancerType ID test is a gene expression-based test for molecularly classifying tumor types. These results are combined with standard clinical and pathological assessments to help physicians determine optimal treatment regimens for patients.

"We are excited to work with Syapse to make our ... clinical testing services available to more health systems," Biotheranostics' President and CEO Nicolas Barthelemy said in a statement. "Integrating data from our molecular tests with the Syapse platform will better help physicians harness individualized patient information to extend lives and reduce costs."

Financial and other terms of the deal were not disclosed.

Recently, Syapse established a consortium with Intermountain Healthcare, Stanford Cancer Institute, and Providence Health & Services that focuses on cancer data sharing between clinics and health systems. Earlier this year, the Palo Alto, California-based company raised $25 million in a Series C financing round which it is using to develop new applications for its platform.